Vertically integrated pharmaceutical
company in the Baltic States


Mildronate® is the leading agent of the cardiovascular group, antiischemic agent of a metabolic action:

  • Acts as antiischemic cell protector in patients with angina pectoris, chronic heart failure, brain circulation disorders. 
  • Improves reduced physical capacity and mental function in the case of ischemia and in healhty people.


Due to its unique mechanism of action Mildronate®, depending on the prescribed dose, is widely used for the treatment of different heart and vascular diseases, as well as for the improvement of work capacity of healthy people at physical and mental overloads and during rehabilitation period. 

In February 2010 «Grindeks» successfully finished the clinical trial on the influence of the brand product Mildronate® on the treatment of angina. Publication in "Seminars in Cardiovascular Medicine, 2010; 16:3" on results of clinical trial "Mildronate improves the exercise tolerance in patients with stable angina: results of a long term clinical trial".


  • 250 mg capsules N60
  • 500 mg capsules N60
  • Injection 10% 5 ml N10